1. Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy.
- Author
-
De, Arka, Charak, Swati, Bhagat, Naveen, Rathi, Sahaj, Verma, Nipun, Premkumar, Madhumita, Taneja, Sunil, Sharma, Aman, Goel, Kapil, Singh, Virendra, and Duseja, Ajay
- Subjects
- *
HEPATITIS C virus , *HEPATITIS C , *ANTIRETROVIRAL agents , *MIXED infections , *LIVER function tests ,SOFOSBUVIR - Abstract
Hepatitis C virus (HCV) infection is more prevalent in people living with HIV‐AIDS (PLHA) and portends a poorer prognosis. Pharmacokinetic studies suggest the absence of significant interaction between velpatasvir and dolutegravir which has been recently recommended as part of preferred first‐line antiretroviral therapy (ART) regimens by WHO. However, clinical data on the use of velpatasvir‐based regimen in PLHA taking dolutegavir is lacking. Hence, we aimed to assess the efficacy and safety of sofosbuvir and velpatasvir (SOF + VEL) in HCV and HIV coinfected patients on dolutegravir‐based ART. Forty‐five consecutive PLHA with HCV coinfection on dolutegravir‐based ART were prospectively enrolled. All patients were treated SOF + VEL for 12 weeks. Complete haemogram, liver and renal function tests were assessed at baseline, 4 weeks and at end of treatment. Sustained virological response (SVR) was assessed at 12 weeks after end of treatment. The majority were males (95.5%) with a mean age of 32.8 ± 12.3 years. Cirrhosis was present in 6 (13.3%) patients. All patients completed 12 weeks of therapy with SOF + VEL, but SVR could not be assessed in two patients. Forty‐two (97.7%) of the remaining 43 patients attained SVR‐12. SVR‐12 rate was 97.7% and 93.3% by per protocol and intention to treat analysis, respectively. No grade III/IV adverse events were reported, and there was no worsening of blood counts, liver or renal function test parameters. The pan‐genotypic regimen of SOF + VEL is safe and effective in PLHA with HCV coinfection who are on dolutegravir‐based ART. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF